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Abstract
Autologous stem cell transplantation (ASCT) is a feasible procedure for human immunodefi-
ciency virus-1 (HIV-1) lymphoma patients, whose underlying disease and intrinsic HIV-1-
and ASCT-associated immunodeficiency might increase the risk for γ-herpesvirus load per-
sistence and/or reactivation. We evaluated this hypothesis by investigating the levels of
Epstein-Barr virus (EBV)- and Kaposi sarcoma-associated herpesvirus (KSHV)-DNA levels
in the peripheral blood of 22 HIV-1-associated lymphoma patients during ASCT, highlight-
ing their relationship with γ-herpesvirus lymphoma status, immunological parameters, and
clinical events. EBV-DNA was detected in the pre-treatment plasma and peripheral blood
mononuclear cells (PBMCs) of 12 (median 12135 copies/mL) and 18 patients (median 417
copies/106 PBMCs), respectively; the values in the two compartments were correlated
(r = 0.77, p = 0.0001). Only EBV-positive lymphomas showed detectable levels of plasma
EBV-DNA. After debulking chemotherapy, plasma EBV-DNA was associated with lympho-
ma chemosensitivity (p = 0.03) and a significant higher mortality risk by multivariate Cox
analysis adjusted for EBV-lymphoma status (HR, 10.46, 95% CI, 1.11–98.32, p = 0.04).
After infusion, EBV-DNA was detectable in five EBV-positive lymphoma patients who died
within six months. KSHV-DNA load was positive in only one patient, who died from primary
effusion lymphoma. Fluctuations in levels of KSHV-DNA reflected the patient’s therapy and
evolution of his underlying lymphoma. Other γ-herpesvirus-associated malignancies, such
as multicentric Castleman disease and Kaposi sarcoma, or end-organ complications after
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salvage treatment were not found. Overall, these findings suggest a prognostic and predic-
tive value of EBV-DNA and KSHV-DNA, the monitoring of which could be a simple, comple-
mentary tool for the management of γ-herpesvirus-positive lymphomas in HIV-1 patients
submitted to ASCT.
Introduction
The human γ-herpesviruses, Epstein Barr virus (EBV) and Kaposi sarcoma-associated herpes-
virus (KSHV) are DNA tumor viruses that establish lifelong latent infections in B lymphocytes.
The frequency of their reactivation is associated with altered cell-mediated immune functions,
such as the one occurring in HIV-1 infection, where EBV and KSHV concur in the develop-
ment of AIDS related disorders [1,2]. Also, HIV-1 negative patients who are iatrogenically im-
munosuppressed following allogenic transplantation [3–5] are at risk of developing severe
lymphoproliferative and end-organ diseases, mediated by γ-herpesviruses reactivation [6]. Al-
though rare, cases of γ-herpesviruses related neoplastic and non-neoplastic complications have
been observed in immunocompetent patients who received autologous stem cell transplanta-
tion (ASCT) for haematological diseases [7–11].
Thanks to combination Antiretroviral Therapy (cART), significantly reducing HIV-1 repli-
cation and improving reconstitution of antiviral immunity [12], also HIV-1-associated lym-
phoma patients can be admitted to salvage ASCT-based treatments [13–18]. However, even
when immune reconstitution after ASCT occurs with dynamics overlapping the seronegative
counterpart, skewing of T cell receptor repertoire [19] and lower levels of CD4+ T lymphocytes
are observed during follow-up. Moreover, an increased incidence of opportunistic infections in
the first 100 days post-transplantation has been reported [20].
Due to the intrinsic HIV-1 related immune senescence [21,22] and to the further immuno-
suppression induced by previous cytotoxic treatments, it cannot be excluded that HIV-1 pa-
tients undergoing salvage treatment with ASCT might be at high risk for post-transplant γ-
herpesviruses reactivation and related clinical events. In addition, since 30% to 90% of AIDS-
related systemic lymphomas are associated with γ-herpesviruses [23], their replication may in-
dicate the underlying lymphoma [24–27] that significantly affects prognosis of HIV-1 auto-
transplanted patients [14].
Measuring γ-herpesvirus-DNA load in peripheral blood is now a common laboratory tool
for monitoring γ-herpesvirus infections [28], and several studies have highlighted its value as a
prognostic and predictive parameter in AIDS-related lymphomas [24,25,27,29,30]. In this ret-
rospective analysis, concerning one of the largest mono-institutional series of HIV-1-associated
relapse/refractoring lymphoma patients who underwent ASCT, peripheral blood EBV-DNA
and KSHV-DNA loads were evaluated in order to assess their level and the frequency of γ-her-
pesviruses reactivation, as well as their predictive and prognostic value during the ASCT proce-
dure and follow-up.
Material and Methods
Patients and Samples
This retrospective, observational, virological and immunological study included all consecu-
tive, refractory, or relapsed HIV-1-associated lymphoma patients, who attended our Institute
from 2001 to 2007, received salvage treatment with high dose chemotherapy (HDC) plus
γ-Herpesvirus-DNA in HIV-1 Autotransplanted Patients
PLOS ONE | DOI:10.1371/journal.pone.0116887 February 10, 2015 2 / 16
Competing Interests: The authors have declared
that no competing interests exist.
ASCT, and showed at least 2-month follow-up after transplantation with available samples.
The Ethics Committee of the National Cancer Institute-IRCCS Aviano approved this study,
and a written informed consent was obtained in accordance with the Declaration of Helsinki.
All the patients’ information was de-identified prior to analysis. The ASCT procedure and
pharmacological treatments have been described elsewhere [20,31]. In brief, all the patients
were submitted to intensive, conventional, second-line debulking chemotherapy (DCT) ac-
cording to the type of lymphoma and based on ESHAP (etoposide, cytarabine, cisplatinum,
methylprednisone), DHAOx (dexamethasone, high-dose cytarabine, and oxaliplatinum) or
MINE schemes (mesna, iphosphamide, mitoxantrone, etoposide, prednisolone). DCT contain-
ing Rituximab was administered to 10 out of 11 patients having a CD20-positive non Hodgkin
lymphoma (NHL). Autografts were collected after enhancement of CD34+ stem cell mobiliza-
tion with granulocyte colony stimulating factor. The second phase of the treatment consisted
of a conditioning regimen with HDC BEAM (carmustine, etoposide, cytarabine, melphalan).
Two days after the end of the HDC treatment, the cryopreserved autograft was infused. cART
was administered to all patients during the ASCT procedure. Anti-cytomegalovirus therapy
and/or prophylaxis was administered to 17/22 patients from the beginning of the conditioning
regimen until neutrophil recovery.
Virological and immunological parameters were evaluated before DCT (i.e., at lymphoma
relapse), post-DCT (i.e., immediately before HDC plus autograft infusion), as well as at months
0.5 (aplastic period), 1, 3, 6 and 12 after autograft infusion, namely until recovery of at least
baseline CD4+ T cell counts was attained [20]. Moreover, one case was assessed at year 3 in
conjunction with relapse occurrence. Due to medical history and sampling gaps, plasma and/
or peripheral blood mononuclear cell (PBMC) samples were not always available for all the pa-
tients. Death from any cause and relapse/occurrence of γ-herpesvirus-associated malignances
were considered as events. Moreover, any clinical event other than death or relapse was as-
sessed in correspondence to a γ-herpesvirus quantitative determination.
Information on outcomes was obtained through verification of patients’ vital status and
lymphoma relapse from the date of enrollment to the date of the last visit. The median follow-
up of the patients after autograft infusion was 50 months (range 2–109 months).
In situ Hybridization and Immunohistochemical Analysis
Tissue samples from 19 out of 22 patients at diagnosis were available for pathological revision
and γ-herpesvirus lymphoma status determination. All lymphoma cases were classified accord-
ing to WHO classification system [32]. EBV status was determined by EBV-Encoded RNAs
(EBER) in situ hybridization, and immunohistochemical analysis for latent membrane protein
(LMP-1) expression on formalin-fixed, paraffin-embedded tissue sections. KSHV lymphoma
status was assessed in available cases with potential KSHV-associated histology (i.e., one
plasmablastic lymphoma, one extracavitary/solid variant of primary effusion lymphoma) or
with positive KSHV viremia (one diffuse large B cell lymphoma (DLBCL) of immunoblastic
type). KSHV status was determined by immunohistochemical analysis for latent LANA-1
(KSHV ORF-73) expression on formalin-fixed, paraffin-embedded tissue sections.
Viral Load Quantification
Cryo-preserved sample aliquots of 200 μl plasma and of about 2 × 106 PBMCs were processed
for DNA extraction with the QIAamp blood Mini kit (Qiagen), according to the manufactur-
er’s instructions. EBV-DNA and KSHV-DNA were measured by real time TaqMan PCR by
using the ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems), as previously
described [29–33]. An EBV-DNA standard curve was generated by 10-fold serial dilutions of
γ-Herpesvirus-DNA in HIV-1 Autotransplanted Patients
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Namalwa genomic DNA, ranging from 5 to 5000 copies per reaction. The analytic validation
assays showed that the sensitivity of the method allowed the quantification of 1, 2.5, and 5 cop-
ies of target DNA per reaction in 33%, 75%, and 90% of cases, respectively. The lack of inhibi-
tory material in each sample was confirmed in an additional reaction seeded with a known
amount of Namalwa genomic DNA. By using this method, EBV-DNA was always undetectable
in plasma and detectable in the PBMCs of 35% of healthy donors [34].
Since the KSHV-DNA and EBV-DNA detection systems were comparable, the number of
KSHV genomes in each sample was calculated from the EBV-DNA standard curve [33]. The
lack of inhibitory material in each sample submitted to KSHV quantification was confirmed in
an additional reaction seeded with a known amount of DNA extracted from a KSHV-infected
BCBL1 lymphoma cell line. Results were expressed as copies of γ-herpesvirus genomes per
milliliter of plasma or per 106 PBMCs. Normalization of the γ-herpesviruses-DNA copies per
106 PBMCs in each peripheral blood DNA sample was obtained by real time TaqMan PCR on
human β-globin gene, as already reported [34]. The β-globin standard curve was obtained by
10-fold serial dilutions of human genomic DNA, ranging from 5 to 5000 copies per reaction.
For statistical purposes, a viral load of zero was assigned to samples in which γ-herpesvirus-
DNA was undetectable.
The absolute lymphocyte subset counts were evaluated by a single platform whole blood lys-
ing technique and with the EPICS XL flow cytometer (Beckman-Coulter), as described else-
where [35]. Plasma HIV-RNA levels were assessed by Quantiplex HIV bDNA assay (3.0
Siemens; detection limit 50 copies/mL). For statistical purposes, a viral load of 49 copies/mL
was assigned to samples with HIV-RNA below the threshold. The HIV-DNA level was mea-
sured by real time PCR with primers and TaqMan probe detecting a 121-bp DNA fragment in
the viral LTR region [31].
Definitions and Statistical Analyses
The Spearman’s rank correlation coefficient was used to analyze the correlation between the vi-
rological and immunological covariates before and post-DCT. Comparisons of matched and
unmatched data were made using Wilcoxon signed rank and Wilcoxon rank sum tests, respec-
tively. McNemar’s test was used to assess the difference between pre- and post-DCT frequency
of EBV-DNA positivity in matched plasma (N = 20) and PBMCs (N = 16) samples. Fisher’s
exact test was used to compare the proportions of patients with EBV-positive lymphoma to
subjects with EBV-negative lymphoma by Rituximab treatment and to evaluate the association
between EBV-DNA positivity post-DCT and the response to DCT assessed by radiological exam-
ination. Response to DCT treatment was evaluated according to International Workshop criteria
[36] as complete response (CR), unconfirmed CR (uCR), partial response (PR), stable disease
and progressive disease. Patients with a decrease in measurable disease ranging from 75% to
100% (CR + uCR) were considered as objective responders, subjects with disease reduction<50%
or stable disease and progressive disease were categorized together as not responders.
The risk of mortality was assessed from the date before DCT until death for any cause after
autograft infusion. The risk of lymphoma relapse was measured from the date before DCT to
lymphoma relapse after autograft infusion defined by radiological examination and immuno-
histological or cytological evaluation of tissue biopsies or needle aspirates. Data were censored
at the time of last available follow-up. Univariate Cox proportional hazards regression analysis
[37] was used to estimate the association between the outcome (mortality and lymphoma re-
lapse) and risk factors including age, histology, Ann Arbor stage, EBV lymphoma status,
Rituximab treatment during DCT, CD4+ T cell counts, CD4/CD8 T cell ratio, CD19+ B cell
counts, HIV-DNA load and EBV-DNA load. The predictive values of the EBV-DNA load on
γ-Herpesvirus-DNA in HIV-1 Autotransplanted Patients
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outcome were examined in a multivariate Cox model adjusted for EBV lymphoma status. The sur-
vival probability curve for plasma EBV-DNA levels was assessed by the Kaplan-Meier survivor
functions, and the differences between variable groups were evaluated by the χ21log-rank K test
[38]. Analyses were performed with SAS System software, version 8.2 (SAS Institute Inc., Cary,
NC, USA, 1999–2001). Results were considered statistically significant at a 2-tailed p-value 0.05.
Results
Patients
Twenty-two consecutive HIV-1 patients with a refractory or relapsed lymphoma who underwent
ASCT and met the selection criteria were included in this study. Their clinical, virological, and im-
munological characteristics before DCT were summarized in Table 1 (data for each patient are re-
ported in S1 and S2 Table). The median age was 42 years (range: 29–67) and the male/female ratio
was 20:2. The most frequent histological subtype was DLBCLNHL (59.1%), followed by Hodgkin
lymphoma (HL) (22.7%). Approximately 96% of the patients had lymphomas at 3 and 4 Ann
Arbor Stages. Four out five HLs and eight out of fourteen NHLs were classified as EBV-positive tu-
mors. Only the extracavitary/solid variant of primary effusion lymphoma (PEL) showed KSHV
ORF-73 and EBER positivity. None of the patients had clinical or histological signs of Kaposi sar-
coma (KS) or multicentric Castleman disease (MCD), neither at diagnosis nor at relapse. The me-
dian CD4+ T cell count was 189 cells/μL (range: 13–630 cells/μL), and 26.3% of the patients had a
severe immune depression (CD4+ T cell count< 100 cells/μL). Detectable HIV-RNA levels were
found in 7/20 patients, with significant post-DCT reduction, as previously described [20]; only in
three patients HIV-RNA remained detectable. Within one year after autograft infusion, 13 patients
(59.1%) were alive, 6 (27.3%) died due to lymphoma’s relapse, and 3 (13.6%) died due to infection.
EBV-DNA Load before DCT
Before DCT, the plasma EBV-DNA was detected in 12/21 patients (57.1%) (overall median:
135 copies/mL; range: 0–105400 copies/mL). EBV-DNA was detected in PBMCs of 18/20
(90.0%) patients (overall median: 417 copies/106 PBMCs; range: 0–33223 copies/106 PBMCs).
All the patients with an EBV-positive lymphoma had always-detectable EBV-DNA in plasma
(median: 1180 copies/mL; range: 68–105400 copies/mL) and in PBMCs (median: 892 copies/
106 PBMCs; range: 123–15498 copies/106 PBMCs). All the patients with EBV-negative lym-
phoma had always-undetectable plasma EBV-DNA, whereas 4/6 (66.7%) showed detectable
EBV-DNA in PBMCs (median: 72 copies/106 PBMCs; range: 11–299 copies/106 PBMCs; p =
0.006 vs. EBV-positive lymphoma patients).
Correlations between EBV-DNA levels and virological and immunological parameters at
the time of lymphoma relapse were reported in Table 2. A significant strong correlation was
observed between EBV-DNA levels in plasma and in PBMCs. Plasma EBV-DNA was negative-
ly correlated with CD4/CD8 T cell ratio, CD19+ B, and with CD3−56+ NK cell counts. In the
cellular compartment, EBV-DNA levels correlated negatively with CD3−56+ NK cell counts.
No significant association between HIV-RNA or HIV-DNA levels and EBV-DNA load was ob-
served, either in plasma or in PBMCs.
EBV-DNA Load Post-DCT
As compared to before, a lower frequency of EBV-DNA positivity in both plasma and
PBMCs was observed post-DCT (5/21 patients, 23.8%; 9/18 patients, 50.0%, respectively).
Analysis on matched data confirmed the significant reduction in the proportion of EBV-DNA
detected in plasma and PBMCs (p = 0.01 and p = 0.04, respectively). In addition, EBV-DNA
γ-Herpesvirus-DNA in HIV-1 Autotransplanted Patients
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levels post-DCT were significantly reduced in both plasma (median: 0 copies/mL; range:
0–1600 copies/mL; p = 0.004 vs. pre-DCT) and PBMCs (median: 6 copies/106 PBMCs; range:
0–1070 copies/106 PBMCs; p = 0.01 vs. pre-DCT). As at the time of lymphoma relapse, the
post-DCT plasma EBV-DNA load was detectable only in patients with EBV-positive lympho-
ma tissue. Of note, the significant decrease in cell-associated EBV-DNA loads between pre-
and post-DCT concerned only the subset of Rituximab treated patients (pre-DCT median: 229
Table 1. Demographic, clinical, histological, virological and immunological characteristics of 22 HIV-
1 lymphoma patients before debulking chemotherapy.
Characteristics Values
Age (median years, range) 42 (29–67)
Gender (n, %)
Female 2 (9.1)
Male 20 (90.9)
Lymphoma status (n, %)
Relapsed lymphoma 17 (77.3)
Refractory lymphoma 5 (22.7)
Ann Arbor Stage (n, %)
2 1 (4.5)
3 9 (41.0)
4 12 (54.5)
Lymphoma histotype (n, %)
DLBCL (5 EBV-positive lymphoma/11 total tested) 13 (59.1)
Immunoblastic 5 (22.7)
Centroblastic 4 (18.2)
Anaplastic 1 (4.5)
NOS 3 (13.6)
Plasmablastic (1 EBV-positive and KSHV-negative lymphoma/1 total tested) 2 (9.1)
Extracavitary/solid variant PEL (EBV- and KSHV-positive lymphoma) 1 (4.5)
ALCL T (EBV-positive lymphoma) 1 (4.5)
Classic HL (4 EBV-positive lymphoma/5 total tested) 5 (22.7)
EBV lymphoma tissue status (n, %)
Positive 12 (54.6)
Negative 7 (31.8)
Unknown 3 (13.6)
Plasma EBV-DNA copies/mL (median, range) 135 (0–105400)
Cell-associated EBV-DNA copies/106 PBMCs (median, range) 417 (0–33223)
HIV-RNA copies/mL (median, range) 49 (49–305426)
Cell-associated HIV-DNA copies/106 PBMCs (median, range) 117 (2–479)
CD4 cells/μl (median, range) 189 (13–630)
CD4/CD8 (median, range) 0.24 (0.06–0.85)
CD19 cells/μl (median, range) 70 (0–419)
CD3−56+ cells/μl (median, range) 56 (3–999)
Plasma and cell-associated KSHV-DNA were detected in two DLBCL immunoblastic lymphomas (one
KSHV-negative in lymphoma tissue; one unknown) and in one extracavitary/solid variant of PEL (KSHV-
positive in lymphoma tissue). DLBCL diffuse large cell lymphoma; PEL, primary effusion lymphoma; NOS,
not otherwise speciﬁed; ALCL, anaplastic large cell lymphoma; HL, Hodgkin’s lymphoma; EBV, Epstein
Barr virus; PBMCs, peripheral blood mononuclear cells.
doi:10.1371/journal.pone.0116887.t001
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copies/106 PBMCs; pre-DCT range: 0–33223 copies/106 PBMCs; post-DCT median: 0 copies/
106 PBMCs; post-DCT range: 0–0 copies/106 PBMCs; p = 0.02). EBV-positive lymphomas
showed higher residual cell-associated EBV-DNA levels (median: 154 copies/106 PBMCs;
range: 0–1024 copies/106 PBMCs) as compared to EBV-negative lymphomas (median: 6 cop-
ies/106 PBMCs; range: 0–197 copies/106 PBMCs; p = 0.04), and a lower frequency of them
were treated with Rituximab (16.7% EBV-positive lymphomas vs. 85.7% EBV-negative lym-
phomas, p = 0.006).
Post-DCT, the negative correlation between plasma EBV-DNA and CD4/CD8 T cell ratio
was maintained (r = −0.45, p = 0.04). A positive significant correlation between EBV-DNA in
PBMCs and CD19+ B cell counts emerged (r = 0.69, p = 0.002). A persistent EBV-DNA in plas-
ma was associated with the absence of an objective response to DCT (p = 0.03). The values of
some demographic, clinical, and laboratory parameters in predicting the risk of mortality and
lymphoma relapse were calculated (Table 3). In univariate Cox regression analysis, only post-
DCT EBV-DNA positivity in plasma or PBMCs were associated with a significantly higher
mortality risk (HR: 5.88, 95% CI: 1.40–24.66; p = 0.02 and HR: 5.52, 95% CI: 1.08–28.16; p =
0.04, respectively) and with an increased risk, although not statistically significant, of develop-
ing lymphoma relapse during follow-up post-autograft infusion (HR: 4.41, 95% CI: 0.94–20.67;
p = 0.06; HR: 4.52, 95% CI: 0.85–24.10; p = 0.08, respectively). Given the significant prognostic
value of EBV-DNA load on mortality and the concordance between EBV-DNA and EBV lym-
phoma status before DCT, multivariate Cox analysis adjusted for EBV lymphoma status was
performed. The results indicated that plasma EBV-DNA remained the only prognostic variable
for mortality (HR: 10.46, 95% CI: 1.11–98.32; p = 0.04). Survival analyses using the Kaplan-
Meier method further supported that patients with detectable post-DCT plasma EBV-DNA
had poorer survival than did patients with undetectable post-DCT plasma EBV-DNA (20% vs.
81% at month 24; p = 0.007) (Fig. 1).
EBV-DNA Load after Autograft Infusion
During follow-up after autograft infusion, three patients died due to fatal infections within the
first six months after transplantation and two of them, who had an EBV-positive lymphoma,
showed EBV-DNA in plasma and PBMCs at the aplastic period, immediately before develop-
ing a life-threatening CMV infection (plasma EBV-DNA: 95 and 57 copies/mL; cell-associated
EBV-DNA: 1063 and 2540 copies/106 PBMCs).
Lymphoma relapse occurred in 7/22 patients (31.8%), and EBV lymphoma status was known
for 6 of them. Three had an EBV-positive lymphoma and, concomitantly, presented detectable
EBV-DNA in both compartments (plasma EBV-DNA: 33160, 2573, and 13410 copies/mL;
PBMCs EBV-DNA: 37561, 1313 and 187 copies/106 PBMCs). They died for disease progression
Table 2. Spearman’s rank correlation coefﬁcients between EBV-DNA levels in plasma or PBMCs compartment and virological or immunological
parameters before debulking chemotherapy.
Plasma EBV-DNA Coefﬁcient (r) p-value Cell-associated EBV-DNA Coefﬁcient (r) p-value
EBV-DNA in PBMCs 0.77 0.0001
HIV-RNA −0.08 0.75 HIV-RNA 0.25 0.32
HIV-DNA −0.07 0.88 HIV-DNA 0.16 0.52
CD4/CD8 −0.47 0.04 CD4/CD8 −0.44 0.07
CD19 # −0.49 0.03 CD19 # −0.24 0.34
CD3−56+ # −0.67 0.002 CD3−56+ # −0.61 0.008
EBV, Epstein Barr Virus; PBMCs, peripheral blood mononuclear cells, #, cells/μl
doi:10.1371/journal.pone.0116887.t002
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within four months after autograft infusion. Three relapsed patients had an EBV-negative
lymphoma and showed undetectable plasma EBV viremia before and close to the relapse. Two
died 13 and 14 months thereafter, and one was still alive at the last follow-up. For the remaining
relapsing patient, EBV lymphoma status was unknown, and EBV viremia could not be assessed.
For the remaining 12 patients still alive after transplantation, evidence for serious γ-herpes-
virus-associated end-organ diseases was not found when γ-herpesvirus viremia was assessed.
Table 3. Hazard ratio (HR) and corresponding 95% conﬁdence interval (CI) for mortality and lymphoma relapse evaluated by demographic,
clinical, histological, virological and immunological parameters.
N (%) Mortality Lymphoma Relapse
HR 95%CI p-Value HR 95%CI p-Value
Age (years)
42 11 (50.0) 1 † 1 †
>42 11 (50.0) 1.21 (0.32–4.51) 0.78 2.46 (0.48–12.72) 0.28
Lymphoma histology
High grade NHL 17 (77.3) 1 † 1 †
HL 5 (22.7) 1.07 (0.22–5.15) 0.94 0.63 (0.08–5.29) 0.67
Stage (Ann Arbor)
2–3 10 (45.5) 1 † 1 †
4 12 (54.5) 0.90 (0.24–3.37) 0.88 0.88 (0.20–3.96) 0.87
Rituximab
yes 10 (45.5) 1 † 1 †
no 12 (54.5) 2.21 (0.53–8.55) 0.29 2.56 (0.49–13.36) 0.26
CD4 post-DCT‡(cells/μL)
< 200 12 (57.1) 1 † 1 †
 200 9 (42.9) 0.72 (0.17–3.04) 0.66 1.77 (0.40–7.93) 0.45
CD4/CD8 post-DCT‡
 0.28 11 (52.4) 1 † 1 †
> 0.28 10 (47.6) 1.09 (0.27–4.39) 0.90 1.55 (0.35–6.94) 0.57
CD19 post-DCT‡(cells/μL)
 1 11 (52.4) 1 † 1 †
> 1 10 (47.6) 2.6 (0.62–10.95) 0.19 2.02 (0.45–9.04) 0.36
Cell-associated HIV-DNA post-DCT‡(copies/106 PBMCs)
< 70 9 (47.4) 1 † 1 †
 70 10 (52.6) 1.51 (0.36–6.38) 0.57 5.42 (0.65–45.21) 0.12
EBV lymphoma tissue status‡
Negative 7 (36.8) 1 † 1 †
ositive 12 (63.2) 1.04 (0.25–4.37) 0.96 0.60 (0.12–2.96) 0.53
Plasma EBV-DNA post-DCT‡(copies/mL)
0 16 (76.2) 1 † 1 †
 1 5 (23.8) 5.88 (1.40–24.66) 0.02 4.41 (0.94–20.67) 0.06
Cell-associated EBV-DNA post-DCT‡(copies/106 PBMCs)
0 9 (50.0) 1 † 1 †
 1 9 (50.0) 5.52 (1.08–28.16) 0.04 4.52 (0.85–24.10) 0.08
†, reference category
‡, the sum does not add up to the total because of missing values
DCT, debulking chemotherapy; NHL, non Hodgkin’s lymphoma; HL, Hodgkin’s lymphoma; PBMCs, peripheral blood mononuclear cells.
doi:10.1371/journal.pone.0116887.t003
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New γ-herpesvirus-associated malignances, such as MCD or KS, were not clinically and/or his-
tologically diagnosed until the last visit. In the 63 plasma samples analyzed until year one after
transplantation, EBV-DNA was always negative, except for samples from two patients, who
showed a sporadic increase in plasma EBV viremia at months 0.5 (324 copies/mL) and 12
(1000 copies/mL), respectively. The first observed viral rise was associated with a persistent
fever after recovery from a sepsis; the second one occurred together with appearance of lymph-
adenopathy and with suspension of antiviral therapy with Famciclovir for an extended cutane-
ous herpes zoster. Cell-associated EBV-DNA was detected with increasing frequency from
month 0.5 to 12 after autograft infusion (4/12 patients at month 0.5, 11/12 patients at month
12; p = 0.01). At year one, the median level of EBV-DNA in PBMCs was 316 copies/106
PBMCs (range: 0 −2083 copies/106 PBMCs), it did not correlate with the B cell counts (r =
0.07, p = 0.83), but, as observed post-DCT, it was inversely correlated with CD4/CD8 T cell
ratio (r = −0.74, p = 0.006). Post-autograft infusion immunological and virological data for
each patient are reported in S3 Table.
KSHV-DNA Load during ASCT Procedure
Before DCT, the KSHV-DNA load was detected in plasma samples of 3/16 patients (18.8%)
(55, 5936, 57765 copies/mL, in patient #8, #18, #7, respectively); the last two subjects also
showed detectable KSHV-DNA in PBMCs (199025 and 14 copies/106PBMCs in patients #18
and #7, respectively). Patients #7 and #8 had an immunoblastic lymphoma, patient #18 was di-
agnosed with an extracavitary/solid variant of PEL. Tissues for KSHV lymphoma status
Figure 1. Kaplan-Meier estimates of overall survival by plasma EBV-DNA post-DCT in HIV-1-associated lymphoma patients.DCT,
debulking chemotherapy.
doi:10.1371/journal.pone.0116887.g001
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assessment were available for patients #8 and #18, who showed a KSHV-negative and KSHV-
positive tumor, respectively.
Post-DCT, the plasma KSHV load in patients #8 and #7 became undetectable, while in pa-
tient #18 a 83% decrease was observed. All three patients showed negative KSHV-DNA in
PBMCs.
After autograft infusion, the KSHV-DNA and EBV-DNA loads were detectable and consis-
tently increased with the same dynamics during three months after transplantation in one pa-
tient (#18) (Fig. 2). At month 3, evolution of the initially diagnosed extracavitary/solid variant
of PEL to classic PEL was documented, and the patient died 30 days later. Of note, a sharp rise
in the plasma KSHV-DNA and EBV-DNA load between month 0.5 to 1 preceded that one in
PBMCs. In this patient, the histological revision of lymphoma tissue at diagnosis and relapse
after transplantation revealed the co-expression of KSHV ORF-73 and EBER in the tumor
cells.
Figure 2. EBV-DNA (dashed line) and KSHV-DNA (solid line) load dynamics in plasma (A) and in
PBMCs (B) during pre- and post- transplantation in patient #18.DCT, debulking chemotherapy.
doi:10.1371/journal.pone.0116887.g002
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Discussion and Conclusions
Several studies have highlighted the association of γ-herpesviruses with AIDS-related systemic
lymphomas [23, 26], evidencing the important contribution of γ-herpesvirus infection to lym-
phoma genesis in the context of heavy immune deficiency. Moreover, in AIDS-related lympho-
ma patients undergoing ASCT, the immune system is severely compromised by the HIV-1
infection, the tumor itself, prior CT cytotoxic effects, and by ablative conditioning finalized to
stem cell infusion. For this reason as well as the severity of the underlying disease, these pa-
tients could be at high risk of relapse or of developing new γ-herpesvirus-related neoplastic and
non-neoplastic diseases. To the best of our knowledge, this is the first study evaluating EBV-
DNA and KHSV-DNA viremia in one of the largest mono-institutional cohorts of HIV-1-asso-
ciated lymphoma patients submitted to ASCT in order to assess the frequency and the levels of
γ-herpesviruses reactivation and their prognostic and predictive value during the ASCT proce-
dure and follow-up.
In this cohort, we found a high percentage of EBV-positive lymphoma cases, in agreement
with literature highlighting a role of EBV in lymphoma development, in concert with immune
suppression and, presumably, other oncogenic factors [39,40]. At the time of lymphoma re-
lapse, plasma EBV-DNA was absent in patients with EBV-negative lymphoma, as reported for
healthy donors [34], while it was always detectable in those with an EBV-positive lymphoma.
On the contrary, cell-associated EBV-DNA was found in all EBV-positive patients and in a
high proportion of the EBV-negative lymphoma patients. It is worth noting that the EBV-
DNA load in both compartments was significantly associated with compromised adaptive and
innate immunity. In particular, the inverse correlation between NK cells and EBV-DNA load
supports the role of this immunological population in controlling EBV-associated tumor gene-
sis, as evidenced by recent data in murine tumor models [41]. Overall, these results highlighted
that EBV-DNA levels could mirror both the presence of an EBV-positive lymphoma and/or
the lack of immunological control of active EBV replication, possibly fostering the genesis/pro-
gression of the lymphoma, as suggested in pre-clinical studies [42,43]. These data evidence the
challenge in the interpretation of this marker, as a consequence of the dual nature of the γ-her-
pesvirus viremia, i.e., naked tumor-derived viral DNA or virional tumor/benign replication-de-
rived DNA. At present, available molecular techniques that can distinguish among these
species are not conclusive and not applicable in the setting of routine monitoring [44–46]. Nev-
ertheless, our study highlighted a complete agreement between EBV lymphoma status and
EBV-DNA load only in the plasma compartment, suggesting that most of the plasma EBV-
DNA could be tumor-derived and, when compared with cell-associated EBV-DNA, could be
more specific in indicating the presence of the lymphoma.
A link between plasma EBV viremia and tumor burden emerged also post-DCT, where the
reduced but persistent plasma EBV-DNA load was present only in EBV-associated lymphomas
and was related to poor DCT response assessed by radiological examination. In addition, in
EBV-positive lymphoma patients, the residual plasma EBV-DNA load significantly predicted
poor survival following transplantation, hence resembling the association between lymphoma
chemosensitivity and survival after salvage treatment in a similar series of HIV-1 patients [14].
Concerning the EBV-DNA in PBMCs, our results indicate that the purging of the cell-associat-
ed EBV-DNA load by debulking treatment was complete in patients treated with DCT plus
Rituximab, confirming that Rituximab was more targeted and effective in destroying the B cell
compartment. Since among EBV-positive lymphoma patients only three were CD20-positive,
the high cell-associated EBV-DNA levels in these subjects could be ascribed to the absence of
Rituximab treatment. As already reported by other authors [47–49], overall these findings con-
firmed that, compared with γ-herpesvirus load in PBMCs, γ-herpesvirus-DNA in plasma is
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more specific in indicating residual disease and could be useful in prognosis evaluation of
EBV-positive tumours.
An estimation of the relationship between KSHV-DNA levels and immune parameters, ra-
diological response to DCT or survival factors was prevented by the low frequency of KSHV-
DNA peripheral blood positivity in this as in other series of AIDS-related lymphomas [27,29].
One patient with diagnosis and relapse of extracavitary/solid variant of PEL, co-expressing
EBV and KSHV in the lymphomatous cells, showed always-positive plasma KSHV-DNA and
EBV-DNA before and after DCT. Moreover, a sharp rise of plasma KSHV-DNA and EBV-
DNA load preceded that one in PBMCs and the onset of a classic PEL after transplantation. In
the first month after autograft infusion, we observed plasma and cell-associated γ-herpesvirus
viremia though this patient was in a context of a seriously compromised immune system with
complete absence of peripheral blood B cells. Considering the evolution of the disease in this
patient, it is not excludible that γ-herpesvirus load in both compartments represents the lym-
phoma load rather than immunedepression-induced γ-herpesvirus reactivation. These obser-
vations highlight that quantitative KSHV-DNA determination in peripheral blood might be a
simple parameter useful in selecting patients who need KSHV-DNA monitoring, especially in
light of cases of KSHV reactivation described in HIV-negative patients after transplantation
[10,11,50].
Evidence on the potential utility of the γ-herpesvirus viremia, in particular for EBV-DNA,
has also been shown after autograft infusion. In fact, the EBV-DNA load in both compartments
increased not only just before occurrence of life-threatening opportunistic infections, but also
in a considerable proportion (43%) of relapses. All these patients had EBV-positive lympho-
mas. In addition, they had a shorter follow-up post-relapse than did the aviremic and EBV-
negative lymphoma relapsing patients, mirroring evidences supporting a worse prognosis of
EBV-positive than EBV-negative lymphomas [51–53].
In the living subjects with complete remission after transplantation, plasma EBV-DNA was
mainly negative. By contrast, a progressive increase in the frequency of EBV-DNA positivity in
PBMCs was observed and occurred without development of EBV-associated clinical symptoms
and relationship with reconstituted B cell numbers. This finding could be the result of viral re-
activation consequent to low immunosurveillance, as suggested by the negative association be-
tween the CD4/CD8 T cell ratio and EBV-DNA in PBMCs. A definitive interpretation of EBV
viremia in PBMCs would benefit from the definition of threshold values.
Presently, no guidelines on a threshold value for EBV-DNA load with clear clinical signifi-
cance in lymphoproliferations are available due to lack of international consensus on the best
calibrator, specimen type, or unit of reporting [54,55]. Furthermore, the chemotherapy regi-
men is an important influencing factor on tumor-associated EBV-DNA levels, but a useful clin-
ical cut-off indicating residual disease has still not been established. It follows that reliance on a
viral load threshold per se to predict γ-herpesvirus-associated disease jeopardizes early detec-
tion of lymphoma, mostly in previously chemo-treated patients. Our study supports previous
findings emphasizing plasma γ-herpesvirus-DNA load as a prognostic and predictive parame-
ter in lymphomas both associated and not associated with HIV-1 [24–27,29,30,47,48], and it
suggests that plasma residual γ-herpesvirus load might be a convenient candidate surrogate
marker of residual disease [49]. To improve the predictive value of cellular EBV-DNA positivi-
ty, EBV-DNAmeasurements should be included within a prognostic score model combining B
cell counts, T cell immunosuppression, EBV specific T cell reactivity [56] and the context of
the patients’ chemotherapeutic plan.
Despite the weaknesses, such as the retrospective nature of the investigation, the small num-
ber of patients, the lack of a protocol schedule envisaging frequent sample collection, and the
impossibility of computing an EBV-DNA reference threshold useful in results interpretation,
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some observations can be made from this study. Indeed, this is the first one describing the pe-
ripheral γ-herpesvirus viremia in one of the largest mono-institutional cohorts of relatively ho-
mogeneous relapse/refractoring HIV-1-associated lymphoma patients submitted to ASCT. It
was found that salvage treatment does not expose the patients to develop new γ-herpesvirus-as-
sociated malignances or end-organ diseases. The evidences also indicated that plasma EBV-
DNA positivity is associated with EBV-positive lymphomas, deep immune deficiency, tumor
chemosensitivity, and early mortality after transplantation. Finally, the γ-herpesvirus-DNA
load could be a useful inexpensive marker for clinical monitoring of γ-herpesvirus-positive
HIV-1-associated lymphoma patients submitted to ASCT and could aid decision-makers in de-
fining treatment options.
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